INSIST trial: MMF vs Tac in SS-ILD N=25 pts 👉No significant diff between MMF & TAC in mean change in FVC at 24 weeks [2.52%, 95% CI (-10.3 to 5.18)p=0.500] 👉No SAEs noted in both grps Larger studies w/ longer ffup needed. #ACR23 ABST2595 @RheumNow https://t.co/cqpnxyMDmv

I think crown belongs to the 🐱💜 🤗Top Influencers of #ACR23 👉 @ACRheum @rheum_cat @RheumNow @drdavidliew @EBRheum @realcc @KDAO2011 https://t.co/UfNdj8u7cP via @symplur https://t.co/b71OeZS7Jj

Sex bias in RA: time to stop blaming hormones? https://t.co/uPq87r4Ndv https://t.co/Yleu2LDV3g

SpA Sleuths: The Case of Undiagnosed IBD #ACR23 As rheums, we are medical detectives investigating complex and often elusive autoimmune and inflammatory conditions. https://t.co/eRxlaoohbi https://t.co/dtXcCXKXql

Watch: Another TYK2 Ticks the Boxes Dr. Janet Pope discusses late-breaking abstract L12 presented at #ACR23. https://t.co/1SGuIFOWt6 https://t.co/tb4LRbmfiI

#ACR23 – Day 1 Report The day began with a bang with the Year in Review that featured the sage insights of Drs. Philip Seo and Tomas Mustelin about the scientific and clinical rheumatology highlights from the past year. https://t.co/a79M2boHRH https://t.co/5P18ybazGK

Taylor et al. Novel blood assay for sero+ and sero- RA. Differentiates well from other diseases. May be very valuable for sero- RA diagnosis = sensitivity 83.7%, +LR 21.46, and -LR 0.17. Needs validation. Abstr#2586 #ACR23 @RheumNow https://t.co/jw41F8YohE https://t.co/kXi3km0b07

Last abstract of #ACR23 was #ACRBest Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis Great performance, even with seroneg RA A blood test to: diagnose ?phenotype ?identify best b/tsDMARD Could be massive Peter Taylor ABST2586 @RheumNow https://t.co/tJX2jXV0Oe